RxDoctor Payments Data

Amber Yarrison, PA

Physician Assistant · Charlotte, NCNPI 1821555384

Payments from drug & device makers

$7,476in general payments, 2019–2025

Across 387 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AstraZeneca$977
  • AbbVie$899
  • Novo Nordisk$733
  • Pfizer$628
  • Amgen$448
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$7,476100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,476 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$35,036
Medicare patients
166
Services billed
415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide25$29,087
FarxigaDapagliflozin Propanediol37$28,123
OzempicSemaglutide20$22,777
EliquisApixaban23$19,027
KerendiaFinerenone12$10,376
Repatha SureclickEvolocumab19$10,302
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,747
SynthroidLevothyroxine Sodium14$1,596
Rosuvastatin Calcium114$1,217
Atorvastatin Calcium98$734
Gabapentin27$685
Levothyroxine Sodium70$603
Duloxetine Hcl57$572
Amlodipine Besylate69$543
Pantoprazole Sodium35$454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$977$34,87048 claims
Lilly USA, LLCMounjaro$1,169$29,08725 claims
Novo NordiskOzempic$733$22,77720 claims
PfizerEliquis$628$19,02723 claims
BayerKerendia$211$10,37612 claims
AbbVieSynthroid$899$1,59614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →